Cancer cachexia: it's time for more clinical trials

Area of Science:

• Oncology
• Metabolic Syndrome
• Clinical Nutrition

Background:

• Cancer cachexia (CC) is a severe condition linked to at least 20% of cancer deaths.
• It involves anorexia, body weight loss, and significant loss of adipose and skeletal muscle tissue.
• CC severely diminishes patients' quality of life and response to cancer therapies.

Purpose of the Study:

• To highlight the critical need for effective therapeutic strategies against cancer cachexia.
• To emphasize the importance of muscle wasting as the primary driver of functional impairment in CC.
• To advocate for prospective, randomized, controlled trials to evaluate drug efficacy.

Main Methods:

• Review of current understanding of cancer cachexia pathophysiology.
• Analysis of preliminary findings from pharmacological interventions in animal models and early clinical trials.
• Identification of gaps in clinical evidence regarding CC treatments.

Main Results:

• Current therapeutic strategies for CC show limited effectiveness.
• Pharmacological approaches targeting anorexia, catabolism, and anabolism have shown promise in preclinical and preliminary clinical studies.
• Clinical data supporting these interventions remain scarce and inconclusive.

Conclusions:

• Muscle wasting is the hallmark of CC, driving fatigue and respiratory issues via hyperactivated proteolytic pathways.
• There is an urgent need for robust clinical trials to identify drugs that can reverse lean muscle loss and improve patient quality of life.
• Evaluating drug effectiveness in improving nutritional status and quality of life in cancer cachexia patients is paramount.